379 related articles for article (PubMed ID: 10684711)
1. Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system.
Kolfschoten GM; Pinedo HM; Scheffer PG; Schlüper HM; Erkelens CA; Boven E
Gynecol Oncol; 2000 Mar; 76(3):362-8. PubMed ID: 10684711
[TBL] [Abstract][Full Text] [Related]
2. Use of nude mouse xenografts as preclinical drug screens: in vivo activity of established chemotherapeutic agents against melanoma and ovarian carcinoma xenografts.
Taetle R; Rosen F; Abramson I; Venditti J; Howell S
Cancer Treat Rep; 1987 Mar; 71(3):297-304. PubMed ID: 3815395
[TBL] [Abstract][Full Text] [Related]
3. Phase II preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study.
Boven E; Winograd B; Berger DP; Dumont MP; Braakhuis BJ; Fodstad O; Langdon S; Fiebig HH
Cancer Res; 1992 Nov; 52(21):5940-7. PubMed ID: 1394220
[TBL] [Abstract][Full Text] [Related]
4. Novel phosphonium salts display in vitro and in vivo cytotoxic activity against human ovarian cancer cell lines.
Manetta A; Gamboa G; Nasseri A; Podnos YD; Emma D; Dorion G; Rawlings L; Carpenter PM; Bustamante A; Patel J; Rideout D
Gynecol Oncol; 1996 Feb; 60(2):203-12. PubMed ID: 8631539
[TBL] [Abstract][Full Text] [Related]
5. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts.
Giavazzi R; Garofalo A; Ferri C; Lucchini V; Bone EA; Chiari S; Brown PD; Nicoletti MI; Taraboletti G
Clin Cancer Res; 1998 Apr; 4(4):985-92. PubMed ID: 9563894
[TBL] [Abstract][Full Text] [Related]
6. The role of glutathione (GSH) in determining sensitivity to platinum drugs in vivo in platinum-sensitive and -resistant murine leukaemia and plasmacytoma and human ovarian carcinoma xenografts.
Goddard P; Valenti M; Kelland LR
Anticancer Res; 1994; 14(3A):1065-70. PubMed ID: 8074451
[TBL] [Abstract][Full Text] [Related]
7. [Predictability of preclinical evaluation of anticancer drugs by human gastrointestinal cancer--nude mouse panel].
Fujita M; Fujita F; Sakamoto Y; Sugimoto T; Shimozuma K; Taguchi T
Gan To Kagaku Ryoho; 1991 Jul; 18(9):1429-37. PubMed ID: 1854213
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity of drug resistance in human breast and ovarian cancers.
Kern DH
Cancer J Sci Am; 1998; 4(1):41-5. PubMed ID: 9467045
[TBL] [Abstract][Full Text] [Related]
9. Glutathione, glutathione S-transferase alpha and pi, and aldehyde dehydrogenase content in relationship to drug resistance in ovarian cancer.
Tanner B; Hengstler JG; Dietrich B; Henrich M; Steinberg P; Weikel W; Meinert R; Kaina B; Oesch F; Knapstein PG
Gynecol Oncol; 1997 Apr; 65(1):54-62. PubMed ID: 9103391
[TBL] [Abstract][Full Text] [Related]
10. [Sensitivity test of anticancer agents using human tumor xenografts in nude mice with special reference on correlation between clinical effects and chemotherapy].
Nosoh Y; Yoshinaka K; Nishimawari K; Hirono M; Tani T; Niimoto M; Hattori T
Gan No Rinsho; 1984 Jul; 30(9 Suppl):1181-5. PubMed ID: 6433069
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity of human non-small cell lung cancer xenografts to cyclophosphamide and cisplatin.
Mattern J; Wayss K; Volm M
In Vivo; 1987; 1(1):23-6. PubMed ID: 2856516
[TBL] [Abstract][Full Text] [Related]
12. [Application of nude mouse-human cancer xenograft system for sensitivity test of anticancer drugs].
Fujita M; Taguchi T
Gan To Kagaku Ryoho; 1982 Apr; 9(4):606-15. PubMed ID: 7184418
[TBL] [Abstract][Full Text] [Related]
13. Clinical studies on a new screening assay for anticancer agents using nude mice and isotopic evaluation.
Noso Y; Niimi K; Nishiyama M; Hirabayashi N; Toge T; Niimoto M; Hattori T
Cancer Res; 1987 Dec; 47(23):6418-22. PubMed ID: 3677085
[TBL] [Abstract][Full Text] [Related]
14. Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts.
Boven E; van der Vijgh WJ; Nauta MM; Schlüper HM; Pinedo HM
Cancer Res; 1985 Jan; 45(1):86-90. PubMed ID: 4038381
[TBL] [Abstract][Full Text] [Related]
15. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines.
Johnson SW; Laub PB; Beesley JS; Ozols RF; Hamilton TC
Cancer Res; 1997 Mar; 57(5):850-6. PubMed ID: 9041185
[TBL] [Abstract][Full Text] [Related]
16. Complete inhibition of human ovarian cancer xenografts in nude mice by suramin and cis-diamminedichloroplatinum(II).
Kikuchi Y; Hirata J; Hisano A; Tode T; Kita T; Nagata I
Gynecol Oncol; 1995 Jul; 58(1):11-5. PubMed ID: 7789875
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneity of glutathione content in human ovarian cancer.
Lee FY; Vessey A; Rofstad E; Siemann DW; Sutherland RM
Cancer Res; 1989 Oct; 49(19):5244-8. PubMed ID: 2766292
[TBL] [Abstract][Full Text] [Related]
18. In vitro growth and drug sensitivity of tumor colony-forming units from human tumor xenografts.
Taetle R; Koessler AK; Howel SB
Cancer Res; 1981 May; 41(5):1856-60. PubMed ID: 7214353
[TBL] [Abstract][Full Text] [Related]
19. In vivo model development of cisplatin-resistant and -sensitive A2780 human ovarian carcinomas.
Rose WC; Basler GA
In Vivo; 1990; 4(6):391-6. PubMed ID: 2103379
[TBL] [Abstract][Full Text] [Related]
20. Effect of five antineoplastic agents on tumor xenografts with different growth rates.
Mattern J; Wayss K; Volm M
J Natl Cancer Inst; 1984 Jun; 72(6):1335-9. PubMed ID: 6587154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]